These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 10813041)

  • 1. New PI active against many strains.
    AIDS Patient Care STDS; 1999 Sep; 13(9):568. PubMed ID: 10813041
    [No Abstract]   [Full Text] [Related]  

  • 2. New resistance score for tipranavir.
    Poveda E
    AIDS Rev; 2008; 10(2):127. PubMed ID: 18615125
    [No Abstract]   [Full Text] [Related]  

  • 3. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.
    Back NK; van Wijk A; Remmerswaal D; van Monfort M; Nijhuis M; Schuurman R; Boucher CA
    AIDS; 2000 Jan; 14(1):101-2. PubMed ID: 10714580
    [No Abstract]   [Full Text] [Related]  

  • 4. The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line.
    Mazza F; Tronconi E; Valerio A; Groettrup M; Kremer M; Tossi A; Benedetti F; Cargnel A; Atzori C
    J Eukaryot Microbiol; 2006; 53 Suppl 1():S144-6. PubMed ID: 17169036
    [No Abstract]   [Full Text] [Related]  

  • 5. Viral resistance to protease inhibitors.
    Smart T
    GMHC Treat Issues; 1995 Jun; 9(6):1, 4-5. PubMed ID: 11362685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitors: drug resistance and cross resistance overview.
    James JS
    AIDS Treat News; 1995 Nov; (no 235):3-5. PubMed ID: 11363046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conference looks at HIV drug resistance.
    Chang HE
    GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue regimens: the value of protease-inhibitor boosting.
    Segal-Maurer S; Schütz M
    Body Posit; 2001 Sep; 14(9):11-3. PubMed ID: 11693112
    [No Abstract]   [Full Text] [Related]  

  • 9. Human immunodeficiency virus. Protease uninhibited.
    Richman DD
    Nature; 1995 Apr; 374(6522):494. PubMed ID: 7700370
    [No Abstract]   [Full Text] [Related]  

  • 10. On the issue of cross-resistance between protease inhibitors.
    Birch C
    AIDS; 1998 Apr; 12(6):680-1. PubMed ID: 9583615
    [No Abstract]   [Full Text] [Related]  

  • 11. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
    Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.
    Hagen SE; Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Markoski LJ; Steinbaugh BA; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Hupe D; Nouhan C; Gracheck SJ; Saunders JM; VanderRoest S
    J Med Chem; 1997 Nov; 40(23):3707-11. PubMed ID: 9371233
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 15. Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
    Lu Z; Bohn J; Rano T; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5311-4. PubMed ID: 16203148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance to protease inhibitors].
    Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
    Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
    J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to protease inhibitors.
    Kuritzkes DR
    J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
    Condra JH; Schleif WA; Blahy OM; Gabryelski LJ; Graham DJ; Quintero JC; Rhodes A; Robbins HL; Roth E; Shivaprakash M
    Nature; 1995 Apr; 374(6522):569-71. PubMed ID: 7700387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding protease inhibitor potency: the intersection of exposure, efficacy, and resistance.
    Schapiro JM
    AIDS Read; 2001 Jun; 11(6):311-5. PubMed ID: 11449924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.